Zuzana PIŇÁKOVÁ1,2, Martin CHORVÁTH1,2,3, Elena BOLJEŠIKOVÁ1, Dalibor ONDRUŠ2

1Klinika radiačnej onkológie SZU a OÚSA, Bratislava, prednostka MUDr. E. Bolješiková, CSc.
2Klinika stereotaktickej rádiochirurgie OÚSA a VŠZaSP sv. Alžbety, Bratislava, prednosta prof. M. Šramka, DrSc.
3I. onkologická klinika LF UK a OÚSA, Bratislava, prednosta prof. MUDr. D. Ondruš, DrSc.

SUMMARY
Prostate cancer (PCa) is the most common urological malignancy in males. Treatment strategy depends on diagnosis (histopathological grade, stage of disease and the risk group). Radiotherapy plays an important role in the treatment of patients with PCa. Modern technologies allow to cover the target volume with a high dose of radiation, while sparing surrounding healthy tissues. Intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), image-guided radiotherapy (IGRT), stereotactic body radiotherapy (SBRT) and brachytherapy can be used in treatment of localized PCa.

Key words: prostate cancer, intensity modulated radiotherapy, volumetric modulated arc therapy, image-guided radiotherapy, stereotactic body radiotherapy, brachytherapy.
Lek Obz (Med Horizon), 2020, 69 (3): 90 – 98